Sorafenib is a multikinase inhibitor used as a first-line therapy for hepatocellular carcinoma, including advanced and unresectable disease, and it functions as a comparator/prior treatment option in clinical studies. Its primary role is antitumor therapy, and the provided key facts note synergistic activity with saquinavir in vitro and in a nude mouse model, consistent with combination-based enhancement of efficacy. Recent literature also links sorafenib exposure to altered tumor glycosylation: treatment was associated with truncated O-glycan formation, while sorafenib-resistant liver cancer cells showed hypersialylation and increased Siglec-7/9 ligands, suggesting an immune-evasion phenotype. These findings connect sorafenib not only to direct cancer control but also to glycoimmune checkpoint biology, especially the ST3GAL1–Siglec-7/9 axis. Overall, sorafenib remains a clinically important HCC drug, with newer studies refining how resistance and immune escape may emerge during therapy.
Hepatocellular carcinoma
- Sorafenib is described as a first-line therapeutic agent for hepatocellular carcinoma and advanced liver cancer. (PMID:41687749)
- A 2026 Free Radical Biology & Medicine study (PMID:41687749) reported synergistic antitumor activity when sorafenib was combined with saquinavir in vitro and in a nude mouse model.
- A 2026 Cancer Immunology, Immunotherapy study (PMID:41961075) found that sorafenib treatment was associated with truncated O-glycan formation in liver cancer cells.
- Sorafenib-resistant liver cancer cells showed hypersialylation and increased Siglec-7/9 ligands, implicating glycoimmune checkpoint remodeling in resistance. (PMID:41961075)
Unresectable hepatocellular carcinoma
- Sorafenib was previously used as a comparator/prior treatment option for unresectable hepatocellular carcinoma. (PMID:41981891)
- The CheckMate 9DW plain-language summary (Future Oncology, 2026) places sorafenib in the treatment landscape for unresectable advanced liver cancer. (PMID:41981891)
- Its role as a historical standard helps contextualize newer immunotherapy combinations being evaluated against prior systemic therapy. (PMID:41981891)